Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds William Blair Initiates Coverage On Aehr Test Systems with Outperform Rating

William Blair Initiates Coverage On Aehr Test Systems with Outperform Rating

William Blair analyst Jed Dorsheimer initiates coverage on Aehr Test Systems (NASDAQ:AEHR) with a Outperform rating.

byBenzinga Newsdesk

October 17, 2022

1 minute read

William Blair analyst Jed Dorsheimer initiates coverage on Aehr Test Systems (NASDAQ:AEHR) with a Outperform rating.

Curaleaf Being Sued In PA For Breach Of Commercial Lease

By Joana Scopel

October 27, 5:10 PM

Regent Development, a Pennsylvania real estate company, is suing Curaleaf Holdings Inc.

CSE:CURA

U-Haul Holding Co. Files For Mixed Shelf; Size Not Disclosed

By Benzinga Newsdesk

December 20, 9:09 AM

- Sec Filing

UHAL

Dyne Therapeutics Receives FDA Fast Track Designation For DYNE-251 For The Treatment Of Duchenne Muscular Dystrophy

By Benzinga Newsdesk

October 31, 7:30 AM

Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that the

DYN

News

Reported Saturday, Lilly’s Tirzepatide Outperformed Placebo In MASH Resolution, With More Than Half Of Patients Showing Fibrosis Improvement At 52 Weeks

By Benzinga Newsdesk

June 10, 3:38 AM

SYNERGY-NASH results were presented at the European Association for the Study of the Liver Congress 2024 and simultaneously published in The New England Journal of Medicine INDIANAPOLIS, June 8,

LLY

William Blair Initiates Coverage On Aehr Test Systems with Outperform Rating

Related Posts

Curaleaf Being Sued In PA For Breach Of Commercial Lease

U-Haul Holding Co. Files For Mixed Shelf; Size Not Disclosed

Dyne Therapeutics Receives FDA Fast Track Designation For DYNE-251 For The Treatment Of Duchenne Muscular Dystrophy

Reported Saturday, Lilly’s Tirzepatide Outperformed Placebo In MASH Resolution, With More Than Half Of Patients Showing Fibrosis Improvement At 52 Weeks